Introduction {#s1}
============

As one of the most common non-epithelial neoplasms, gastrointestinal stromal tumours (GISTs) are located in the stomach (55.6%), small intestine (31.8%), colon and rectum (6.0%), and oesophagus and abdominal cavity (6.2%) and have various clinical features ranging from asymptomatic to nonspecific abdominal discomfort, pain, haemorrhage and tumour abdominal ([@B18]); the incidence of GISTs is 10-15 cases per million per year in 19 countries ([@B30]). It is not necessary for GIST patients to exhibit liver metastasis or intraperitoneal dissemination to perform an assessment of the tumour risk. However, clinicopathological factors, including the tumour size, mitotic count and anatomical location, were associated with cancer patient survival ([@B5]; [@B26]; [@B17]), and complete surgical resection remains the primary treatment method for localized GISTs ([@B14]). GISTs can be characterized by the expression of CD117 or PDGFRA protein in neoplastic cells, and a gain-of-function mutation may exist in the type III receptor tyrosine kinase gene (c-KIT or PDGFR-α) at the genetic level ([@B13]; [@B11]). KIT is a receptor tyrosine kinase that is upregulated in the interstitial cells of Cajal, which are pacemakers responsible for digestive movement ([@B2]). KIT mutations frequently occur in exons 9, 11, 13 and 17 ([@B12]; [@B4]) and play a vital role in GIST pathogenesis ([@B27]; [@B13]). In addition, a PDGFR-α mutation, which is present in 1/3 of KIT-negative GIST patients, mainly affects exons 12, 14 and 18 and can induce tyrosine kinase autophosphorylation, activate signalling molecules containing SH2 domains, and initiate various cancer-related pathways ([@B37]).

Additionally, deregulated circular RNAs (circRNAs) were investigated in acute myeloid leukaemia, breast cancer, gastric cancer, and prostate cancer ([@B28]; [@B40]) and found to be involved in a variety of tumour-specific progression events, such as proliferation, invasion and metastasis ([@B21]; [@B22]; [@B35]; [@B44]; [@B28]). These deregulated circRNAs exhibit cell- or tissue-specific expression, exist in a steady state on tissues, in the cellular nucleus and cytosol, on extracellular exosomes, and in body fluid and may serve as potential biomarkers of cancer ([@B10]). Several deregulated circRNAs have been reported to contribute to promoting cell proliferation, such as circPVT1 in gastric tumours, circABCB10 in breast tumours and circBANP in colon tumours ([@B28]). The downregulation of circITCH was also observed in bladder carcinoma, oesophageal squamous cell carcinoma, lung cancer, colon and rectal cancer and hepatocellular carcinoma ([@B28]). circRNAs, which have a head-to-tail connected ring structure of exon or intron cyclization, are generated from pre-mRNAs ([@B36]) and play a sponge role by absorbing microRNAs for binding to the miRNAs of target genes, which could be indirectly influenced by circRNAs forming competing endogenous RNA (ceRNA) networks with circRNAs ([@B20]). The overexpression of circITCH passively modulated diverse tumour cellular processes by binding miR-17 via specific miRNA-binding sites, which had evident effects on the aggressive biological behaviours mediated by the circITCH/miR-17, miR-224/p21, and PTEN axis ([@B44]). We previously revealed that the differentially expressed circRNAs (circ_0062019 and circ_0057558) and the host gene SLC19A1 of circ_0062019 could be used as potential novel biomarkers of prostate cancer ([@B40]). However, to note, no altered circRNAs have been reported in GISTs, and we still lack adequate in-depth knowledge about the biological function of circRNAs in GISTs.

In this study, we first analysed the ceRNA expression profile in gastrointestinal stromal tumour using high-throughput circRNA gene microarray and verified the differential circRNAs in GISTs by qRT-PCR. Our exploration of the circRNA-miRNA-mRNA network could help by adding a new dimension to the study of the molecular mechanisms of GISTs and provide new directions for GIST diagnosis and treatment.

Materials and Methods {#s2}
=====================

Patients and Specimens {#s2_1}
----------------------

This study included patients with GIST who underwent partial or complete resection between Sept 2012 and Oct 2017 at Shanghai Public Health Clinical Center, Fudan University, China. The study was approved by the Medical Ethics Commission of Shanghai Public Health Clinical Center. All patients had understood all aspects of the informed consent and signed the informed consent forms before undergoing surgeries. During the operation, 68 pairs of GIST and adjacent normal gastrointestinal tissue samples were collected from obvious lesions and the corresponding gastric or intestinal tissues, which were 1--3 centimetre distant from the tumour edge and contained no obvious cancer cells. After removal from the body, the fresh samples were rapidly intensively chilled in liquid nitrogen within 5 min of excision to avoid degradation. Then, the frozen specimens were stored in a −80°C refrigerator. All enrolled patients were diagnosed for the first time through a pathological examination before undergoing surgical resection. The definitive diagnosis of all cases required tissue biopsy, which relied on endoscopic ultrasound-guided fine-needle aspiration. The tumour histological grading were based on malignancy risk stratification of the gastrointestinal stromal cell tumours by tumour size, mitotic count, and location ([@B26]).

Cell Line, Plasmid and Cell Transfection {#s2_2}
----------------------------------------

The human gastrointestinal stromal tumour cell lines GIST-T1 and GIST-882 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The GIST-T1 cells were cultured in Mcoy5A's medium, and the GIST-882 cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS) (HyClone, Logan, UT, USA) under the culture conditions of 37°C and 5% CO~2~. A circ_0084097 and an NC control pLCDH-ciR empty vector were synthesized by Geneseed Biotech Co. Ltd. (Guangzhou, China) and transfected into the GIST-T1 cells by using Lipofectamine 2000 reagent (Life Technologies Corporation, Carlsbad, CA, USA) following the manufacturer's protocol. The transfection efficiency was assessed using qRT-PCR.

RNA Purification and SBC ceRNA Microarrays {#s2_3}
------------------------------------------

The total RNA was isolated and purified with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and a TIANGEN total RNA Isolation Kit (TIANGEN, Beijing, China) according to the manufacturer's protocol. The isolated RNAs were stored at −80°C. The RNA was qualified, and the RNA integrity number was determined by an Agilent 2100 bioanalyser, while the RNA concentration was analysed using a NanoDrop-2000 spectrophotometer (NanoDrop, USA). For the ceRNA microarray, the included RNA samples were obtained from 3 pairs of GIST and adjacent normal gastrointestinal tissue samples. cRNA was synthesized and amplified with an Agilent Low Input Quick Amp WT Labeling Kit (Santa Clara, CA, US) and can be labelled by cyanine 3-labelled CTP with T7 RNA polymerase. The labelled cRNA was purified by an RNeasy mini kit (Qiagen, USA) and loaded onto SBC Human (4\*180K) ceRNA microarrays including 88,371 circRNAs and 18,853 mRNAs (Shanghai Biotechnology corporation, Shanghai, China). The signals were scanned by an Agilent G2565CA Microarray Scanner. The raw data were obtained by Agilent Feature Extraction (v10.7). After normalization of the raw data with R software, the differentially expressed mRNAs and circRNAs were filtrated according to the fold change and Student t-test. The normalized signal value is the value calculated by log2. All ceRNAs with a fold change (FC) ≥ ± 2, a p-value \< 0.05 and intensity \> 7.0 were included for further statistical analysis. The complete ceRNA array datasets were deposited in the Gene Expression Omnibus (GEO) database under accession number GSE131481.

Regulatory Network and Pathway Analysis of the Differential mRNAs and the Host Genes of the Differential circRNAs in GISTs {#s2_4}
--------------------------------------------------------------------------------------------------------------------------

To further investigate the functions of these differential mRNAs in GISTs, the functions of the differential genes were annotated with GO and KEGG pathway analyses ([@B40]). CircInteractome (<https://circinteractome.nia.nih.gov/>) was used to predict the putative miRNAs of the three circRNAs and the potential circRNA/miRNA interaction ([@B8]). Targetscan7.2 (<https://circinteractome.org./vert_72>) was used to predict the targeted miRNAs of the three host genes. We overlapped the two predicted results. Finally, we selected the top miRNAs with the highest context scores (score \>85) to establish a circRNA-miRNA-host gene network, which was illustrated by Cytoscape3.5.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis of the Differentially Expressed circRNAs and Their Host Genes in GISTs {#s2_5}
------------------------------------------------------------------------------------------------------------------------------------------

In total, 3 circRNAs were chosen for experimental validation by qRT-PCR. As an exoribonuclease, RNase R can only act on RNA from its 3' to 5' end but does not degrade circRNA ([@B32]). Therefore, to distinguish the expression between the linear mRNA and circRNA, total RNAs were incubated for 20 min at 37°C with or without RNase R (Epicentre Technologies, Madison, WI), and the resulting RNAs were purified using an RNAsimple Total RNA Kit (Tiangen, Beijing, China) and transcribed into cDNA. The cDNAs were synthesized with reverse transcriptase using a PrimeScript^TM^ RT reagent Kit with gDNA Eraser (TaKaRa). The PCR comprised 50 ng cDNA, 10 μl of 2 x PCR Master mix (SYBR Premix Ex Taq^TM^ II kit) (TaKaRa), 0.8 μl primer forward (10 μM), 0.8 μl primer reverse (10 μM), and 0.4 μl of ROX reference Dye and was performed on an ABI ViiA 7 (Applied Biosystems, DE, USA) as follows: denaturation at 95°C for 10 min, amplification at 95°C for 15 s over 40 cycles, followed by annealing and extension at 60°C for 1 min. The results of the relative expression levels were obtained by calculating the raw data using the 2^-ΔΔCt^ method. 18S rRNA served as an internal control for the normalization. The numbers of exons and exact sequences of circ_0084097 produced from PLAT, circ_0069765 from KIT, and circ_0079471 from ETV1 were validated by Sanger sequencing. All the primers for circ_0084097, circ_0069765, and circ_0079471 were designed by Shanghai Biotechnology corporation and shown in [**Tables S1**](#SM1){ref-type="supplementary-material"} and [**S2**](#SM1){ref-type="supplementary-material"}.

Statistical Analysis {#s2_6}
--------------------

To compare the GIST and adjacent normal gastrointestinal tissue samples, the significance of the relative quantification validation was conducted by Student t-test for the paired analysis. All tests were 2-sided, and p \< 0.05 was regarded as statistical significance. The data were analysed with Statistical Program for Social Sciences (SPSS) 16.0 software (SPSS, Chicago, IL, USA).

Results {#s3}
=======

Differentially Expressed mRNAs and circRNAs in GISTs {#s3_1}
----------------------------------------------------

The characteristics of the GIST patient population and the clinical details of the three samples from the GIST patients chosen for the SBC ceRNA arrays are shown in [**Table S3**](#SM1){ref-type="supplementary-material"}. The ceRNA arrays were performed to investigate the differentially expressed mRNAs and circRNAs in GISTs. Volcano plots were used to present the significant differences in the extracted data between the GIST and adjacent normal gastrointestinal tissue samples and show the expressed difference in mRNAs ([**Figure S1A**](#SM1){ref-type="supplementary-material"}) and circRNAs ([**Figure S1B**](#SM1){ref-type="supplementary-material"}) between the GIST and adjacent tissues. Based on the differences in their expression levels, hierarchical clustering showed the differentially expressed mRNA ([**Figure 1A**](#f1){ref-type="fig"}) and circRNA ([**Figure 1B**](#f1){ref-type="fig"}) expression profile among 3 pairs of GIST and adjacent normal gastrointestinal tissue samples. In total, 1,815 mRNAs (839 upregulated mRNAs and 976 downregulated mRNAs) ([**Table 1**](#T1){ref-type="table"}) and 5,770 circRNAs (3,122 upregulated circRNAs and 2,648 downregulated circRNAs) ([**Table 2**](#T2){ref-type="table"}) were differentially expressed between the GIST and adjacent normal gastrointestinal tissue samples (p \< 0.05 and FC ≥ ± 2). After screening the differentially expressed mRNAs by retrieving the GEO database (GSE112) and utilizing GEO2R in analysing the array data ([**Table S4**](#SM1){ref-type="supplementary-material"}), Venn diagrams were generated to show the 387 common differentially expressed genes (DEGs) selected in our array and GEO dataset GSE112 ([**Figure 1C**](#f1){ref-type="fig"}). Finally, 95 DEGs were also identified as the host genes of DEcircRNAs in GISTs. In total, 54 circRNA host genes were upregulated, and 41 DEcircRNA host genes were downregulated in the GIST tumour tissues from these three GISTs patients, which was consistent with the expression level of the circRNAs (p \< 0.05 and FC ≥ ± 2) ([**Figure 1D**](#f1){ref-type="fig"} and [**Table 3**](#T3){ref-type="table"}).

![Heatmaps and Venn Diagrams showing the differential mRNAs, circRNAs and their host genes in GISTs. Heat maps of the differentially expressed mRNAs **(A)** and circRNAs **(B)**. Venn Diagrams showing that the common 387 mRNAs **(C)** were from differential mRNAs in the GEO dataset (GSE112) and our ceRNA array, and 95 common mRNAs were from overlapped 387 genes and differently expressed circRNA host genes in our ceRNA array **(D)**.](fgene-10-00825-g001){#f1}

###### 

Partially differentially expressed mRNAs in GIST.

  Gene Symbol   Gene bank Accession No   Fold change   *p*-values
  ------------- ------------------------ ------------- ------------
  MC4R          NM_005912                518.09        0.031
  F2RL2         NM_004101                312.59        0.032
  LY6H          NM_001130478             205.12        0.008
  NPPC          NM_024409                141.15        0.001
  FBN2          NM_001999                133.50        0.019
  OBSCN         NM_001271223             132.13        0.000
  PTPRH         NM_002842                124.36        0.000
  ASTN1         NM_004319                112.92        0.027
  SCG5          NM_001144757             102.57        0.010
  ITGA10        NM_003637                94.89         0.006
  TBX5          NM_000192                93.62         0.037
  PRKCQ         NM_006257                92.00         0.001
  ANO1          NM_018043                84.12         0.001
  ABCA12        NM_173076                80.20         0.005
  CIT           NM_001206999             63.97         0.000
  SH3GL3        NM_001301109             63.28         0.004
  KIT           NM_000222                61.06         0.011
  DPP10         NM_001178036             57.54         0.018
  TENM1         NM_001163278             56.20         0.001
  ROBO2         NM_001290040             54.12         0.007
  GYG2          NM_003918                −215.06       0.016
  PKD1L2        NM_052892                −228.15       0.014
  AZGP1         NM_001185                −242.01       0.004
  MFAP5         NM_003480                −242.88       0.002
  ABCA8         NM_001288985             −258.21       0.002
  VIT           NM_053276                −279.41       0.001
  CYP4B1        NM_001099772             −281.41       0.004
  PI16          NM_153370                −306.57       0.004
  HBA1          NM_000558                −315.48       0.008
  ITLN1         NM_017625                −335.62       0.004
  ALDH1L1       NM_012190                −375.76       0.024
  PLIN4         NM_001080400             −392.80       0.009
  CFD           NM_001928                −565.13       0.001
  C14orf180     NM_001286400             −681.24       0.016
  PPP1R1A       NM_006741                −709.72       0.015
  HRASLS5       NM_054108                −740.50       0.017
  ADH1C         NM_000669                −846.95       0.001
  ADH1B         NM_001286650             −886.39       0.021
  ADH1A         NM_000667                −969.78       0.003
  TUSC5         NM_172367                −2204.07      0.025

###### 

Partially differentially expressed circRNAs in GIST.

  ------------------------------------------------------------------------
  circRNA_ID         Gene bank\     Fold change   *p*-values   Host gene
                     Accession No                              
  ------------------ -------------- ------------- ------------ -----------
  hsa_circ_0065978   NM_001161581   598.50        0.020        POC1A

  hsa_circ_0016772   NM_001098623   253.92        0.008        OBSCN

  hsa_circ_0016774   NM_001098623   233.44        0.005        OBSCN

  hsa_circ_0016775   NM_001098623   231.51        0.004        OBSCN

  hsa_circ_0016776   NM_001098623   213.33        0.007        OBSCN

  hsa_circ_0016773   NM_001098623   209.56        0.004        OBSCN

  hsa_circ_0016778   NM_001098623   201.52        0.004        OBSCN

  hsa_circ_0069236   NM_001145847   184.99        0.006        PROM1

  hsa_circ_0016780   NM_001098623   180.51        0.001        OBSCN

  hsa_circ_0016779   NM_001098623   169.85        0.005        OBSCN

  hsa_circ_0023311   NM_018043      137.75        0.001        ANO1

  hsa_circ_0028697   NM_001206999   125.79        0.003        CIT

  hsa_circ_0028694   NM_001206999   124.24        0.000        CIT

  hsa_circ_0028687   NM_001206999   113.21        0.000        CIT

  hsa_circ_0045305   NM_138363      107.60        0.000        CEP95

  hsa_circ_0073782   NM_001999      103.58        0.023        FBN2

  hsa_circ_0023310   NM_018043      103.44        0.000        ANO1

  hsa_circ_0003570   NM_014661      98.82         0.000        FAM53B

  hsa_circ_0023309   NM_018043      98.25         0.000        ANO1

  hsa_circ_0073792   NM_001999      94.47         0.019        FBN2

  hsa_circ_0081375   NM_001185      −102.41       0.001        AZGP1

  hsa_circ_0037139   NM_000517      −105.37       0.020        HBA2

  hsa_circ_0025368   NM_003480      −106.22       0.000        MFAP5

  hsa_circ_0035024   NM_001015001   −107.93       0.006        CKMT1A

  hsa_circ_0037141   NM_000558      −113.19       0.021        HBA1

  hsa_circ_0006751   NM_014241      −115.81       0.003        PTPLA

  hsa_circ_0017695   NM_024693      −119.12       0.038        ECHDC3

  hsa_circ_0001946   NM_004065      −122.17       0.021        CDR1

  hsa_circ_0002091   NM_014241      −130.33       0.000        PTPLA

  hsa_circ_0087206   NM_000689      −132.06       0.001        ALDH1A

  hsa_circ_0005754   NM_001103184   −146.44       0.022        FMN1

  hsa_circ_0080888   NM_006379      −159.28       0.001        SEMA3C

  hsa_circ_0025367   NM_003480      −159.49       0.000        MFAP5

  hsa_circ_0080897   NM_006379      −159.96       0.001        SEMA3C

  hsa_circ_0048861   NM_000064      −181.48       0.004        C3

  hsa_circ_0048858   NM_000064      −182.24       0.006        C3

  hsa_circ_0048867   NM_000064      −182.38       0.007        C3

  hsa_circ_0048892   NM_000064      −196.57       0.010        C3

  hsa_circ_0048870   NM_000064      −218.98       0.005        C3

  hsa_circ_0048871   NM_000064      −279.58       0.004        C3
  ------------------------------------------------------------------------

###### 

Partial DEcircRNAs and DEGs as host genes in GISTs.

  circRNA_ID         Gene bank Accession No   Fold change   *p*-values   Host gene   Fold change   *p*-values
  ------------------ ------------------------ ------------- ------------ ----------- ------------- ------------
  hsa_circ_0073782   NM_001999                103.58        0.023        FBN2        133.50        0.019
  hsa_circ_0017609   NM_006257                39.41         0.014        PRKCQ       92.00         0.001
  hsa_circ_0028697   NM_001206999             125.79        0.003        CIT         63.97         0.000
  hsa_circ_0069765   NM_000222                66.92         0.002        KIT         61.06         0.011
  hsa_circ_0056201   NM_001178036             43.76         0.047        DPP10       57.54         0.018
  hsa_circ_0091277   NM_198465                70.33         0.000        NRK         51.90         0.000
  hsa_circ_0079471   NM_004956                36.48         0.005        ETV1        45.36         0.009
  hsa_circ_0008714   NM_001025390             66.38         0.004        AMPD3       33.80         0.003
  hsa_circ_0071585   NM_000892                5.39          0.023        KLKB1       24.89         0.026
  hsa_circ_0086362   NM_002839                65.77         0.009        PTPRD       23.58         0.009
  hsa_circ_0073242   NM_004385                20.36         0.000        VCAN        23.06         0.000
  hsa_circ_0084097   NM_000930                19.09         0.013        PLAT        22.19         0.007
  hsa_circ_0015753   NM_198503                14.62         0.001        KCNT2       19.19         0.007
  hsa_circ_0027663   NM_001135805             29.87         0.001        SYT1        18.99         0.009
  hsa_circ_0055922   NM_201555                24.80         0.008        FHL2        16.85         0.000
  hsa_circ_0047919   NM_152721                6.70          0.041        DOK6        16.10         0.011
  hsa_circ_0052028   NM_002975                16.82         0.003        CLEC11A     16.07         0.003
  hsa_circ_0070911   NM_014278                12.28         0.001        HSPA4L      15.89         0.001
  hsa_circ_0070487   NM_005723                14.36         0.013        TSPAN5      15.41         0.007
  hsa_circ_0069722   NM_145263                29.12         0.002        SPATA18     14.52         0.001
  hsa_circ_0080961   NM_000927                25.22         0.019        ABCB1       12.98         0.001
  hsa_circ_0015816   NM_205860                −19.14        0.020        NR5A2       −9.17         0.024
  hsa_circ_0014229   NM_019554                −41.00        0.008        S100A4      −10.00        0.003
  hsa_circ_0033629   NM_001311                −13.51        0.007        CRIP1       −10.04        0.015
  hsa_circ_0000895   NM_002229                −8.78         0.009        JUNB        −10.11        0.007
  hsa_circ_0070442   NM_007351                −31.47        0.003        MMRN1       −11.11        0.004
  hsa_circ_0013276   NM_001013660             −9.10         0.001        FRRS1       −11.70        0.005
  hsa_circ_0087214   NM_000700                −38.15        0.033        ANXA1       −12.81        0.007
  hsa_circ_0078299   NM_005100                −14.43        0.002        AKAP12      −14.88        0.003
  hsa_circ_0060545   NM_002999                −7.21         0.034        SDC4        −16.55        0.016
  hsa_circ_0032974   NM_006329                −23.91        0.029        FBLN5       −17.26        0.010
  hsa_circ_0000074   NM_002228                −13.85        0.018        JUN         −17.69        0.006
  hsa_circ_0055622   NM_207328                −2.59         0.039        GPT2        −18.34        0.002
  hsa_circ_0046941   NM_002071                −5.80         0.043        GNAL        −23.67        0.002
  hsa_circ_0008591   NM_053025                −18.81        0.025        MYLK        −26.71        0.016
  hsa_circ_0049487   NM_001299                −38.06        0.048        CNN1        −28.60        0.041
  hsa_circ_0070510   NM_016242                −23.03        0.038        EMCN        −31.55        0.029
  hsa_circ_0039466   NM_175617                −11.67        0.001        MT1E        −35.88        0.002
  hsa_circ_0056473   NM_032995                −12.44        0.007        ARHGEF4     −45.11        0.000
  hsa_circ_0003625   NM_032784                −50.11        0.008        RSPO3       −60.82        0.009
  hsa_circ_0025368   NM_003480                −196.57       0.000        MFAP5       −242.90       0.002

Functional Pathway Analysis of Differential mRNAs and circRNA Host Genes in GISTs {#s3_2}
---------------------------------------------------------------------------------

Subsequently, a Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of these differentially expressed mRNAs and the host genes of the differential circRNAs in GISTs was performed to determine the top 5 pathways of the differential mRNAs, which included Biosynthesis of unsaturated fatty acids, Vitamin B6 metabolism, Notch signalling pathway, Dilated cardiomyopathy, ABC transporters and Hypertrophic cardiomyopathy (HCM) ([**Figure 2A**](#f2){ref-type="fig"}); several circRNA host genes were enriched in the pathways of One carbon pool by folate, D-Glutamine and D-glutamate metabolism, ECM-receptor interaction, Adherens junction, and Nicotinate and nicotinamide metabolism ([**Figure 2B**](#f2){ref-type="fig"}). Moreover, several common pathways involved the differentially expressed mRNAs and host genes of differential circRNAs in GISTs, including vascular smooth muscle contraction, Notch signalling pathway, nicotinate and nicotinamide metabolism, N-Glycan biosynthesis, hypertrophic cardiomyopathy (HCM), focal adhesion ECM-receptor interaction, Dilated cardiomyopathy, axon guidance and Arrhythmogenic right ventricular cardiomyopathy (ARVC).

![Functional pathway analysis of targeted genes of predicted miRNAs and competitive and endogenous regulatory network. GO analysis of targeted genes **(A)**, and KEGG analysis of targeted genes **(B)**.](fgene-10-00825-g002){#f2}

KIT-Related circRNA-miRNA-mRNA Regulatory Network Analysis in GISTs {#s3_3}
-------------------------------------------------------------------

Among ceRNA expression profiling in GISTs, we found three circRNAs (circ_0069765, cir_0084097, and circ_0079471) and their host genes (KIT, PLAT, and ETV1) were up-regulated in GISTs. The molecular analysis of KIT becomes one of the two gold standards of diagnosis in GISTs. Mutation in the KIT gene is the key oncogenic drivers in the majority of GISTs ([@B38]), which is also potentiated by a positive feedback circuit that involves the ETS transcription factor ETV1 ([@B9]; [@B38]). Besides, PLAT (Tissue-Type Plasminogen Activator) as a node with VEGFC, PGF and CHD7 in the functional networks was also verified to be significantly enriched in blood vessel development involved in the tissue specificity of GISTs ([@B25]), which pushed us to analyze KIT related circRNA-miRNA-mRNA regulatory network in GISTs. Thus, three circRNAs derived from above parental genes were selected for further investigation although there were some top change circRNAs in [**Table 2**](#T2){ref-type="table"}. circ_0069765, which is located on chr4 q12 (chr4:55569889-55603446), is derived from a non-coding regulatory region of KIT ([**Figure S2A**](#SM1){ref-type="supplementary-material"}). circ_0079471, which is located on chr7 p21.2 (chr7:13949257-13975521), is a regulatory circRNA within a long non-coding region of ETV1 ([**Figure S2B**](#SM1){ref-type="supplementary-material"}). However, circ_0084097 stems from a non-coding regulatory region contained a promoter blank adjacent to the promoter region of PLAT, which is located on chr8 p12 (chr8:42046451-42050729) ([**Figure S2C**](#SM1){ref-type="supplementary-material"}). Based on the miRNA site prediction, we predicted the targeted miRNAs of the three differential circRNAs in circular RNA Interactomem (<https://circinteractome.nia.nih.gov/>) ([@B8]). To obtain insight into reciprocal circRNA, miRNA and mRNA regulation, we constructed a regulatory circRNA-miRNA-mRNA network using Cytoscape software and clarified the interaction among the three circRNAs (circ_0069765, circ_0084097, and circ_0079471), their host genes (KIT, PLAT, and ETV1) and seven predicted miRNAs (miR-144-3p, miR-1246, miR-485-3p, miR-142-3p, miR-142-5p, miR-326 and miR-324-5p), which is shown in [**Figure 3**](#f3){ref-type="fig"}. In the figure, the upregulated circRNAs and their host genes are marked in red, and the downregulated miRNAs that had been reported in previous studies investigating cancer tissues are marked in green. Evidently, miR-144-3p, and miR-485-3p are common target miRNAs of all three host genes (KIT, PLAT, and ETV1), and miR-142-5p is a targeted miRNA of KIT and PLAT. We also found that miR-1246 was predicted as the common targets of both circ_0069765 and circ_0084097 and their host genes (KIT and PLAT), and miR-326 was predicted as the common targets of both circ_0069765 and circ_0079471. Thus, the specific regulatory networks including the three circRNAs (circ_0069765, cir_0084097, and circ_0079471), their host genes (KIT, PLAT, and ETV1) and the three miRNAs (miR-142-5p, miR-144-3p and miR-485-3p) may be key regulators in GISTs.

![Regulatory network analysis of DEcircRNAs, their targeted genes, and predicted miRNAs. circ_0069765, circ_0079471, circ_0084097 and their host genes (KIT, PLAT, and ETV1) in a related regulatory network.](fgene-10-00825-g003){#f3}

Differential circRNAs (circ_0069765, circ_0079471 and circ_0084097) and Their Host Genes Were Verified in GISTs by qRT-PCR {#s3_4}
--------------------------------------------------------------------------------------------------------------------------

The genomic structure shows that circ_0069765 contains six exons from the KIT gene ([**Figure S2A**](#SM1){ref-type="supplementary-material"}), circ_0079471 contains four exons from ETV1 gene ([**Figure S2B**](#SM1){ref-type="supplementary-material"}), and circ_0084097 contains three exons from PLAT gene ([**Figure S2C**](#SM1){ref-type="supplementary-material"}). All the "head-to-tail" splicing sites of the three circRNAs are presented in [**Figure S2**](#SM1){ref-type="supplementary-material"}. The distinct products of these three circRNAs were amplified using outward-facing primers and confirmed by Sanger sequencing ([**Figures S3A--C**](#SM1){ref-type="supplementary-material"}). We found that circ_0069765, circ_0079471 and circ_0084097 were resistant to RNase R, compared to the linear mRNAs (Data not shown). Next, we detected the expression level of circ_0069765, circ_0079471, circ_0084097 and their corresponding host genes by real-time PCR (qRT-PCR) analyses. The relative expression of the three circRNAs (circ_0069765, circ_0079471 and circ_0084097) was evidently upregulated in the GIST tissues compared with that in the adjacent noncancerous tissues (p \< 0.001); in addition, the three host genes, i.e., KIT, PLAT and ETV1, were upregulated (p \< 0.001) ([**Figure 4**](#f4){ref-type="fig"}). The qRT-PCR analyses revealed that 44 of 66 (66.67%) tumours had increased circ_0069765 (4.68-fold); 60 of 65 (92.30%) tumours had increased host gene KIT mRNA (1404.20-fold) expression; 63 of 68 (92.65%) tumours had increased cir_0084097 expression (156.86-fold); 61 of 68 (89.71%) tumours had increased host gene PLAT mRNA (462.43-fold) expression; 59 of 68 (86.76%) tumours had increased circ_0079471 (118.10-fold) expression; and 62 of 66 (93.94%) tumours had increased host gene ETV1 mRNA (678.60-fold) expression. These findings were consistent with the tissue microarray data and showed the significant upregulation tendency of the three circRNAs and three host genes. Finally, we identified that markable positive correlations were present between PLAT and three verified circRNAs (p \< 0.05) ([**Table S5**](#SM1){ref-type="supplementary-material"}). We also noted a non-negative correlation between two circRNAs and ETV1 ([**Table S5**](#SM1){ref-type="supplementary-material"}, \*p \< 0.05). Interestingly, an obvious correlation was observed not only between the genes ETV1 and PLAT (p \< 0.001) but also between the circRNAs circ_0069765 and circ_0079471 and between circ_0079471 and circ_0084097 (p \< 0.05) ([**Table S5**](#SM1){ref-type="supplementary-material"}). To clarify the characteristics of these differential circRNAs and their host genes in GIST cancer, a Pearson correlation analysis was applied to analyse the correlation between these circRNAs/their host genes and the corresponding clinical parameters. As shown in [**Table 4**](#T4){ref-type="table"}, circ_0084097 and its host gene PLAT are negatively correlated with metastasis of tumours significantly related to the stomach (p \< 0.05). PLAT was also negatively correlated with the tumour diameter (p \< 0.05) ([**Table 4**](#T4){ref-type="table"}), indicating that circ_0084097 and PLAT may be related to the early stage of stomach stromal tumour.

![qRT-PCR analysis of the gene expression levels of the three differentially expressed circRNAs and their host genes in GISTs. **(A)** KIT; **(B)** PLAT; **(C)** ETV1; **(D)** circ_0069765; **(E)** circ_0084097; and circ_0079471**(F)**.](fgene-10-00825-g004){#f4}

###### 

Correlation analysis of circ_0084097/PLAT expression in tumour tissue samples of GIST patients and their clinical factors.

  Characteristic               circ_0084097   Person correlation   p-value   PLAT        Person correlation   p-value            
  ---------------------------- -------------- -------------------- --------- ----------- -------------------- --------- -------- -----------
  **Location**                                                     0.310     **0.010**                                  0.284    **0.019**
  Stomach                      15             24                                         13                   26                 
  Other                        19             10                                         21                   8                  
  **Metastasis**                                                   −0.246    **0.045**                                  −0.242   **0.049**
  Yes                          7              4                                          8                    3                  
  No                           26             30                                         25                   31                 
  **Vascular invasion**                                            −0.218    0.074                                      −0.197   0.108
  Yes                          7              3                                          7                    3                  
  No                           27             31                                         27                   31                 
  **Adhesion**                                                     −0.1      0.419                                      −0.198   0.106
  Yes                          15             15                                         19                   11                 
  No                           19             19                                         15                   23                 
  **Maxium tumour diameter**                                       −0.059    0.635                                      −0.298   **0.013**
  \<10 cm                      25             28                                         22                   31                 
  \>10 cm                      9              6                                          13                   3                  
  **NIH grade**                                                    0.106     0.388                                      −0.084   0.496
  low risk                     15             11                                         12                   14                 
  intermediate and high risk   19             23                                         22                   20                 

Bold values denote statistical significance at the p \< 0.05 level.

Discussion {#s4}
==========

In this study, the ceRNA expression profile showed that the mRNA and circRNA expression profile in the gastric stromal tumour tissues was distinguished from that in matched tissues adjacent to the tumour and found that a total of 3,122 circRNAs were significantly upregulated and 2,648 were significantly downregulated in the tumour tissues. More importantly, 95 differentially expressed genes had been filtered by overlapping circRNA host genes and significant mRNAs of GSE112. We found several common pathways involving the differential mRNAs and the host genes of differential circRNAs in GISTs, including vascular smooth muscle contraction, Notch signalling pathway, nicotinate and nicotinamide metabolism, N-Glycan biosynthesis, Hypertrophic cardiomyopathy (HCM), Focal adhesion, ECM-receptor interaction, Dilated cardiomyopathy, Axon guidance, and Arrhythmogenic right ventricular cardiomyopathy (ARVC) ([**Figure 2**](#f2){ref-type="fig"}). Three molecular inhibitors of the Wnt signalling pathway have been reported to be tumour suppressors in various in vitro and in vivo GIST models harbouring a KIT mutation. The Wnt antagonist DKK4 was apparently downregulated in advanced human GISTs ([@B46]). The Notch signalling pathway has also been reported to be a tumour suppressor in GIST cells harbouring a KIT mutation. The downstream target of notch (dominant-negative Hes1) was apparently upregulated in GIST patients with longer relapse-free survival ([@B44]). In addition, the focal adhesion signalling pathway played a critical role in the proliferation of both imatinib-sensitive and resistant GIST cells ([@B46]). We demonstrated that the Wnt, Notch and Focal adhesion signalling pathways are associated with GIST cell proliferation.

Notably, 95 genes were not only differentially expressed linear RNAs but also maternal genes that generated various differentially expressed circular RNAs in our study. circ_0069765, circ_0079471 and circ_0084097 were selected for the validation of the array results, and we detected the expression of these circRNAs in 68 pairs of tissue samples and showed that the three circRNAs were significantly upregulated in tumour tissues, while their host genes KIT, PLAT and ETV1 had a similar rising trend in expression. Furthermore, the expression levels of these three circRNAs and their host genes were also checked in GIST cell lines. We only found that circ_0069765 was significantly upregulated in the GIST-T1 and GIST-882 cells and that circ_0079471 and its host gene ETV1 were overexpressed in the GIST-T1 cells compared to the normal stomach stromal tissue by a qRT-PCR analysis (all p \< 0.05) ([**Figure S4**](#SM1){ref-type="supplementary-material"}).

Web tools for miRNA target-site prediction for circRNA that have a sequence-based recognition system come with the context scores which have the advantage of being predictive for all types of interactions. There is not standard score for selecting top miRNAs. We selected top miRNAs with the high context score (score \> 85) for the three differential circRNAs to establish a circRNA-miRNA-host gene network in GIST ([**Table S6**](#SM1){ref-type="supplementary-material"}) and found that miR-142-3p, miR-142-5p, miR-149, miR-324-5p, miR-326, miR-485-3p and miR-1246 might interact with circ_0069765, circ_0079471 and circ_0084097. Interestingly, miR-1246, miR-142-5p, and miR-324-5p were downregulated in the GIST cells (GIST-882 and GIST-T1) compared to the normal stomach stromal tissue in the qRT-PCR analysis ([**Figures 5A--C**](#f5){ref-type="fig"}). In the analysis of the function of the ceRNAs and their interaction, we confirmed that these three miRNAs were also repressed and that circ_0079471 was upregulated in GIST-T1 cells by overexpression of circ_0084097 ([**Figures 5D--H**](#f5){ref-type="fig"}), which was consistent with our circRNA-miRNA regulatory network analysis in GISTs ([**Figure 4**](#f4){ref-type="fig"}). Thus, these miRNAs may be linked to several host genes, including KIT, PLAT, and ETV1. In GISTs, a KIT proximal domain mutation, especially in exon 11, can induce ligand-independent kinase phosphorylation and activate downstream signal transduction pathway, including AKT, MAPK and STAT ([@B3]). The molecular targeted agent, Imatinib, blocks KIT / PDGFRA signalling by binding the ATP-binding pocket required for phosphorylation and activation of the receptor. The application of imatinib had changed from a single drug model to a combination with surgical treatment, which was essential to complete surgical resection, alleviate the disease, prolong survival and improve the quality of life, especially among postoperative patients ([@B15]). Unfortunately, initially sensitive tumours acquired imatinib resistance due to a KIT secondary mutation. Sunitinib and regorafenib are two additional multikinase inhibitors approved as second- and third-line therapies, respectively, and are available for the treatment of imatinib-resistance GIST ([@B6]; [@B7]). It has been found that non-small cell lung cancer tumourigenesis was suppressed by the overexpression of miR142-5p, which also regulated tumour cell PD-L1 expression and enhanced anti-tumour immunity in pancreatic cancer ([@B16]; [@B33]). The downregulation of miR-142-5p was significantly associated with the recurrence and poor prognosis of gastric cancer (GC) and promoted tumour metastasis by regulating CYR61 expression ([@B43]). miR-144-3p was significantly downregulated in hepatocellular carcinoma, glioblastoma, multiple myeloma and pancreatic cancer and inhibited proliferation, migration and tumour metastasis by targeting SGK3 ([@B39]), FZD7 ([@B1]), c-Met ([@B47]) and FOSB ([@B23]). The repression of miR-485-3p was also found in breast cancer. The overexpression of miR-485-3p can inhibit mitochondrial respiration and breast cancer cell metastasis by inhibiting PGC-1α expression ([@B24]). Low serum levels of miR-485-3p were related to poor survival in patients with glioblastoma ([@B34]). The miR-324-5p-mediated suppression of NF-κB activation was reported to be responsible for inhibition breast cancer cell invasion and migration ([@B29]). The expression of miR-1246 was downregulated in lung cancer cell lines and cervical cancer tissue, was negatively correlated with the clinical stage and inhibited cell invasion and the EMT by targeting CXCR4 ([@B45]; [@B42]). miR-149 was downregulated in ovarian cancer, colorectal cancer and lung cancer. The overexpression of miR-149 increased the drug sensitivity of cancer cells and inhibited the EMT through the FOXM1/cyclin D1/MMP2 axis ([@B19]; [@B41]; [@B31]). Thus, the decreased expression and functional inhibition of these miRNAs in cancer further support our hypothesis that circ_0069765, circ_0079471 and circ_0084097 function to regulate the more comprehensive circRNAs-miRNAs-genes network.

![Gene expression levels of miR-1246, miR-142-5p, and miR-324-5p in GIST-T1 and GIST-882 cells **(A**--**C)** **(A)** miR-1246; **(B)** miR-142-5p; **(C)** miR-324-5p and their expression in GIST-T1 with circ_0079471 by overexpression of circ_0084097 **(D**--**H)** **(D)** circ_0084097; **(E)** circ_0079471; **(F)** miR-1246; **(G)** miR-142-5p; **(H)** miR-324-5p were analysed by qRT-PCR.](fgene-10-00825-g005){#f5}

In summary, the present research revealed the ceRNA expression profiles in GISTs and identified that three circRNAs (circ_0069765, circ_0079471 and circ_0084097) and three host genes (KIT, ETV1 and PLAT) were upregulated in GISTs using qRT-PCR. We further demonstrated that the specific regulatory networks including three circRNAs (circ_0069765, cir_0084097, and circ_0079471), their host genes (KIT, PLAT, and ETV1) and three miRNAs (miR-142-5p, miR-144-3p and miR-485-3p) may be key regulators in GISTs and are likely involved in tumour oncogenesis and progression. In future investigations, it is worth considering the verification of the molecular mechanism of these specific circRNAs to regulate GIST occurrence and development. A greater understanding of the mechanisms of the involvement of specific circRNAs in GIST tumour malignancy is necessary for the identification of possible therapeutic targets.
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